Your browser doesn't support javascript.
loading
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard, Thomas P; Arnoff, Taylor E; Song, Melinda R; Giacomelli, Andrew O; Wang, Xiaofeng; Hong, Andrew L; Dharia, Neekesh V; Wang, Su; Vazquez, Francisca; Pham, Minh-Tam; Morgan, Ann M; Wachter, Franziska; Bird, Gregory H; Kugener, Guillaume; Oberlick, Elaine M; Rees, Matthew G; Tiv, Hong L; Hwang, Justin H; Walsh, Katherine H; Cook, April; Krill-Burger, John M; Tsherniak, Aviad; Gokhale, Prafulla C; Park, Peter J; Stegmaier, Kimberly; Walensky, Loren D; Hahn, William C; Roberts, Charles W M.
Afiliação
  • Howard TP; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Arnoff TE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Song MR; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Giacomelli AO; Harvard Medical School, Boston, Massachusetts.
  • Wang X; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Hong AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Dharia NV; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Wang S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vazquez F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Pham MT; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Morgan AM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Wachter F; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Bird GH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kugener G; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Oberlick EM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Rees MG; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Tiv HL; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.
  • Hwang JH; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Walsh KH; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Cook A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Krill-Burger JM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Tsherniak A; Harvard Medical School, Boston, Massachusetts.
  • Gokhale PC; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Park PJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Stegmaier K; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Walensky LD; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
  • Hahn WC; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Roberts CWM; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Cancer Res ; 79(9): 2404-2414, 2019 05 01.
Article em En | MEDLINE | ID: mdl-30755442
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Proteínas Proto-Oncogênicas / Tumor Rabdoide / Proteínas de Ciclo Celular / Proteínas Proto-Oncogênicas c-mdm2 Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Proteínas Proto-Oncogênicas / Tumor Rabdoide / Proteínas de Ciclo Celular / Proteínas Proto-Oncogênicas c-mdm2 Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2019 Tipo de documento: Article